Summary
This randomised double-blind placebo-controlled trial examined whether a combination of soluble beta-glucan (1-3, 1-6 D-beta glucan) and a native strain of Lactobacillus rhamnosus (Heriz I) could modify immune markers in 30 women with breast cancer receiving chemotherapy. Serum IL-4 decreased significantly in the intervention group compared to placebo (P = 0.005), whilst IL-12 showed a non-significant increase (P = 0.066). The authors conclude the combination may have immunomodulatory potential, though acknowledge the need for larger studies.
Regional applicability
This Iranian study is relevant to United Kingdom practice insofar as it addresses supportive care during chemotherapy using widely available supplement types; however, the isolated probiotic strain is region-specific, and the trial's small sample size (n=30) and modest effect sizes limit direct applicability to UK clinical guidelines. Replication in larger UK or European cohorts would be needed to inform supplementation recommendations within the National Health Service.
Key measures
White blood cell count, neutrophil count, lymphocyte count, monocyte count, serum IL-4 level, serum IL-12 level
Outcomes reported
The study measured white blood cell counts (WBC, neutrophils, lymphocytes, monocytes) and serum levels of IL-4 and IL-12 before and after 21-day supplementation in women undergoing chemotherapy. Primary outcome was the effect of combined beta-glucan and Lactobacillus rhamnosus on immunological markers during the interval between chemotherapy courses.
Topic tags
Dig deeper with Pulse AI.
Ask about this record, its theme or its relevance to UK farming and policy. Pulse AI uses selected catalogue evidence and cites the sources it draws on.